The efficacy and safety of canagliflozin in the treatment of patients with early diabetic nephropathy.
Journal
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
ISSN: 1899-1505
Titre abrégé: J Physiol Pharmacol
Pays: Poland
ID NLM: 9114501
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
02
11
2021
accepted:
28
02
2022
entrez:
31
5
2022
pubmed:
1
6
2022
medline:
3
6
2022
Statut:
ppublish
Résumé
This study aimed to observe the efficacy and safety of canagliflozin in the treatment of patients with early diabetic nephropathy (DN) and investigate its effect in reducing urinary protein levels. A total of 132 patients with DN and normal renal function (estimated glomerular filtration rate >60 ml/min/1.73 m
Identifiants
pubmed: 35639038
doi: 10.26402/jpp.2022.1.06
doi:
Substances chimiques
Canagliflozin
0SAC974Z85
Irbesartan
J0E2756Z7N
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM